Antibiotic stewardship programs with behavioral nudges significantly reduced prescriptions
LOS ANGELES— Every year, about 10 million antibiotic prescriptions are written in emergency departments—and about half of them are inappropriate. Similar problems exist in urgent care centers. Antibiotic overuse leads to a host of issues, including adverse drug effects on patients and accelerating the rise of antibiotic-resistant bacteria, which kill more than 20,000 Americans a year.
Team of scientists developed antibody-based treatment that prevented infection in mice
LOS ANGELES — Researchers from the Los Angeles Biomedical Research Institute (LA BioMed) and Vitalex Biosciences (a spinoff company of LA BioMed) helped lead an experiment that successfully immunized mice against mucormycosis, a fungal infection that is often fatal, potentially paving the way for the development of an immunotherapy for humans.
New study underway to explore disease risk factors
Researchers from the Los Angeles Biomedical Research Institute (LA BioMed) are participating in a novel study to understand why people born in rural communities in the South live shorter and less healthy lives than their counterparts elsewhere in the country.
Post-menopausal women on low-fat diets had materially better outcomes
A team of scientists led by Dr. Rowan Chlebowski of the Los Angeles Biomedical Research Institute (LA BioMed) have discovered that post-menopausal women suffering from breast cancer who eat a low-fat diet have a materially greater rate of survival, according to a new study released today.
Basepaws, a DNA-testing startup for cats, received investments from 2 "sharks"
The cat is out of the bag — Basepaws, a startup sometimes referred to as "23 and Me for cats," picked up two investments totaling $250,000 on an episode of ABC’s "Shark Tank" that aired Sunday, April 28.
Sharks Kevin O’Leary, a software entrepreneur, and Robert Herjavec, who founded a cybersecurity firm, each acquired 5% of the company for $125,000.
Researchers at LA BioMed in Torrance, CA have been working to create a therapeutic vaccine for 2 years to fight infections caused by Candida auris. The lab studies have been most encouraging. With its resistance to anti-fungal drugs, a vaccine is likely the best way to combat the antibiotic-resistant nature of this emerging and deadly pathogen.
Institute recently opened new 78,000 square-foot medical research facility to house award-winning doctors
LOS ANGELES – The Los Angeles Biomedical Research Institute (LA BioMed) announced today that 11 of its investigators are included in America’s Top Doctors. The honor is presented annually, and they are based on recommendations from other physicians and health care professions.
$63-million, four-story, 78,000 square-foot facility is one of the most advanced in the country
LOS ANGELES — The Los Angeles Biomedical Research Institute (LA BioMed) today held the grand opening of its new state-of-the-art medical research building and bioscience incubator on its campus at Harbor-UCLA Medical Center in Torrance.
“The opening of our new medical research building is a milestone for LA BioMed,” said David Meyer, PhD, President and CEO, LA BioMed. “It will allow us to recruit and retain the best investigators, giving them world-class labs and work spaces where they can develop new treatments and therapeutics for years to come.”
Discovery paves the way for new generation of anti-infective
A discovery by researchers at the Los Angeles Biomedical Research Institute (LA BioMed) has uncovered a common blueprint for proteins that have antimicrobial properties. This finding opens the door to design and development of a new generation of anti-infectives active against pathogens that have become resistant to conventional antibiotics.
Product developed at LA BioMed is a safe, economical, available primary therapy
Last night’s episode of CBS’ “60 Minutes” brought much-needed awareness of the hardships faced by the estimated 25 million people around the world living with sickle cell disease. The broadcast highlighted an experimental gene therapy-based treatment that might someday even cure the disease. However, at this time, it is not available to the general public and remains in an experimental stage where potential complications and consistent efficacy are still being evaluated. Also, the procedure is potentially hugely expensive should it ever be commercialized.